- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe active systemic juvenile idiopathic arthritis
- Meeting Date: November 2011
- Public Summary Document (PSD) November 2011 PBAC Meeting - PDF
Tocilizumab – November 2011
Tocilizumab, concentrate for injection, 80 mg in 4 mL, 200 mg in 10 mL and 400 mg in 20 mL, Actemra® - November 2011
Last updated
2 March 2012